Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.
- The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.
- Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone, initially in 60 patients.
- Each company is supplying its respective anti-cancer agent(s) to support the trial.
- Adagene will retain global development and commercialization rights to ADG126.